MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 401–500 of 1,038
Kalikaki, A., Koutsopoulos, A., Trypaki, M., Souglakos, J., Stathopoulos, E., Georgoulias, V, Mavroudis, D., & Voutsina, A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604629 · Cited by 206
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C.-Y., Yang, J. C.-H., & Yang, P.-C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 203
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Dagogo-Jack, I., Yoda, S., Lennerz, J. K., Langenbucher, A., Lin, J. J., Rooney, M. M., Prutisto-Chang, K., Oh, A., Adams, N. A., Yeap, B. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3906 · Cited by 204
Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204
Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1371 · Cited by 203
Self-citationCancer cell plasticity: Impact on tumor progression and therapy response
da Silva-Diz, V., Lorenzo-Sanz, L., Bernat-Peguera, A., Lopez-Cerda, M., & Muñoz, P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.009 · Cited by 203
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 200
Self-citationReduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M., Saunders, R. E., Melnick, M. A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 203
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E. L., Koike, S., Shaw, A. T., Engelman, J. A., & Fujita, N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1385 · Cited by 201
Self-citationBeau-Faller, M., Ruppert, A.-M., Voegeli, A.-C., Neuville, A., Meyer, N., Guerin, E., Legrain, M., Mennecier, B., Wihlm, J.-M., Massard, G., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168d9d4 · Cited by 201
Nishino, M., Jackman, D. M., Hatabu, H., Yeap, B. Y., Cioffredi, L.-A., Yap, J. T., Jänne, P. A., Johnson, B. E., & Van den Abbeele, A. D. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3928 · Cited by 201
Self-citationInhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells
Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A., & Lawrence, T. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6389 · Cited by 201
The emerging role of MET/HGF inhibitors in oncology
Scagliotti, G. V., Novello, S., & von Pawel, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.001 · Cited by 200
Byeon, H. K., Ku, M., & Yang, J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0202-2 · Cited by 197
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Self-citationMet gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
Okuda, K., Sasaki, H., Yukiue, H., Yano, M., & Fujii, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00916.x · Cited by 198
Molecular Pathways: HER3 Targeted Therapy
Gala, K., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 199
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., Andre, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Cytokines in cancer drug resistance: Cues to new therapeutic strategies
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z.-S., Fu, L., & Huang, R.-P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.005 · Cited by 195
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 230
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
De-regulated FGF receptors as therapeutic targets in cancer
Knights, V., & Cook, S. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.001 · Cited by 196
Spiess, C., Merchant, M., Huang, A., Zheng, Z., Yang, N.-Y., Peng, J., Ellerman, D., Shatz, W., Reilly, D., Yansura, D. G., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2621 · Cited by 197
The clinical and functional significance of c-Met in breast cancer: a review
Ho-Yen, C. M., Jones, J. L., & Kermorgant, S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0547-6 · Cited by 197
Emerging roles of deubiquitinases in cancer‐associated pathways
Sacco, J. J., Coulson, J. M., Clague, M. J., & Urbé, S. (2010) · IUBMB Life · doi:10.1002/iub.300 · Cited by 196
MET As a Possible Target for Non–Small-Cell Lung Cancer
Sadiq, A. A., & Salgia, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.9422 · Cited by 195
Yap, T. A., Olmos, D., Brunetto, A. T., Tunariu, N., Barriuso, J., Riisnaes, R., Pope, L., Clark, J., Futreal, A., Germuska, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0367 · Cited by 196
Immune Resistance in Lung Adenocarcinoma
Spella, M., & Stathopoulos, G. T. (2021) · Cancers · doi:10.3390/cancers13030384 · Cited by 193
Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 194
Santoni-Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 194
Haura, E. B., Tanvetyanon, T., Chiappori, A., Williams, C., Simon, G., Antonia, S., Gray, J., Litschauer, S., Tetteh, L., Neuger, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4029 · Cited by 194
AXL kinase as a novel target for cancer therapy
Wu, X., Liu, X., Koul, S., Lee, C. Y., Zhang, Z., & Halmos, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2542 · Cited by 193
Self-citationTumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 194
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
Kodack, D. P., Farago, A. F., Dastur, A., Held, M. A., Dardaei, L., Friboulet, L., von Flotow, F., Damon, L. J., Lee, D., Parks, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.051 · Cited by 193
Self-citationChen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., Xu, C., Wang, Y., Adelmant, G. O., Capelletti, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1671 · Cited by 191
Self-citationSystematic identification of signaling pathways with potential to confer anticancer drug resistance
Martz, C. A., Ottina, K. A., Singleton, K. R., Jasper, J. S., Wardell, S. E., Peraza-Penton, A., Anderson, G. R., Winter, P. S., Wang, T., Alley, H. M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.aaa1877 · Cited by 191
Genetic Changes in Squamous Cell Lung Cancer: A Review
Heist, R. S., Sequist, L. V., & Engelman, J. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824cc334 · Cited by 191
Self-citationThe CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients
Sequist, L. V., Nagrath, S., Toner, M., Haber, D. A., & Lynch, T. J. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181989565 · Cited by 189
Thomson, S., Petti, F., Sujka-Kwok, I., Epstein, D., & Haley, J. D. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9200-4 · Cited by 190
Huang, W.-C., Chen, Y.-J., Li, L.-Y., Wei, Y.-L., Hsu, S.-C., Tsai, S.-L., Chiu, P.-C., Huang, W.-P., Wang, Y.-N., Chen, C.-H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240796 · Cited by 190
Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 188
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Piper-Vallillo, A. J., Sequist, L. V., & Piotrowska, Z. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03123 · Cited by 190
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
“For example, the discovery of MET amplification in a subset of resistant EGFR-mutant lung cancers [14] has now led to promising activity of combination EGFR and MET TKIs [103] in EGFR-mutant lung cancer patients with acquired resistance due to MET amplification.”
BackgroundInfluentialSabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 189
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
Pines, G., Köstler, W. J., & Yarden, Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.019 · Cited by 187
MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
Schildhaus, H.-U., Schultheis, A. M., Rüschoff, J., Binot, E., Merkelbach-Bruse, S., Fassunke, J., Schulte, W., Ko, Y.-D., Schlesinger, A., Bos, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0450 · Cited by 188
Campbell, M. R., Amin, D., & Moasser, M. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1218 · Cited by 188
Kitamura, K., Seike, M., Okano, T., Matsuda, K., Miyanaga, A., Mizutani, H., Noro, R., Minegishi, Y., Kubota, K., & Gemma, A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0448 · Cited by 187
Benedettini, E., Sholl, L. M., Peyton, M., Reilly, J., Ware, C., Davis, L., Vena, N., Bailey, D., Yeap, B. Y., Fiorentino, M., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090863 · Cited by 185
Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
Tang, Z., Du, R., Jiang, S., Wu, C., Barkauskas, D. S., Richey, J., Molter, J., Lam, M., Flask, C., Gerson, S., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604559 · Cited by 185
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Smith, C. C., Paguirigan, A., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T., Chin, C.-S., Asthana, S., Olshen, A., Travers, K. J., et al. (2017) · Blood · doi:10.1182/blood-2016-04-711820 · Cited by 184
Chung, J.-H., Rho, J. K., Xu, X., Lee, J. S., Yoon, H. I., Lee, C. T., Choi, Y. J., Kim, H.-R., Kim, C. H., & Lee, J. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.011 · Cited by 186
Self-citationUnleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
Cortot, A. B., Repellin, C. E., Shimamura, T., Capelletti, M., Zejnullahu, K., Ercan, D., Christensen, J. G., Wong, K.-K., Gray, N. S., & Jänne, P. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2066 · Cited by 185
“Models of drug resistance to EGFR TKIs have typically identified a single molecular event including EGFR T790M and MET amplification (12, 24) Here, we find that the resistance to PF299804 and WZ4002 occurs through a more dynamic and multistep process, which could be more reflective of clinical drug resistance.”
InfluentialSelf-citationMechanisms of drug resistance in kinases
Barouch-Bentov, R., & Sauer, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.546344 · Cited by 181
Novel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A., Newell, E. W., Iyer, N. G., Lim, W.-T., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W.-L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 184
ALKoma: A Cancer Subtype with a Shared Target
Mano, H. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0009 · Cited by 182
De Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Krishnaswamy, S., Kanteti, R., Duke-Cohan, J. S., Loganathan, S., Liu, W., Ma, P. C., Sattler, M., Singleton, P. A., Ramnath, N., Innocenti, F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0070 · Cited by 184
Ou, S.-H. I. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.010 · Cited by 182
“[59] Engelman JA, Zejnullahu K, Mitsudomi T, et al.”
BackgroundNagatsuma, A. K., Aizawa, M., Kuwata, T., Doi, T., Ohtsu, A., Fujii, H., & Ochiai, A. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0360-4 · Cited by 181
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zeng, Z.-S., Weiser, M. R., Kuntz, E., Chen, C.-T., Khan, S. A., Forslund, A., Nash, G. M., Gimbel, M., Yamaguchi, Y., Culliford, A. T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.049 · Cited by 180
The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
Sheng, Q., & Liu, J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.62 · Cited by 181
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Kim, Y., Ko, J., Cui, Z., Abolhoda, A., Ahn, J. S., Ou, S.-H., Ahn, M.-J., & Park, K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0750 · Cited by 175
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
Chen, C.-T., Kim, H., Liska, D., Gao, S., Christensen, J. G., & Weiser, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0754 · Cited by 178
Self-citationTargeting of erbB3 receptor to overcome resistance in cancer treatment
Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 180
Shi, P., Oh, Y.-T., Zhang, G., Yao, W., Yue, P., Li, Y., Kanteti, R., Riehm, J., Salgia, R., Owonikoko, T. K., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.021 · Cited by 177
Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Bahcall, M., Sim, T., Paweletz, C. P., Patel, J. D., Alden, R. S., Kuang, Y., Sacher, A. G., Kim, N. D., Lydon, C. A., Awad, M. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0686 · Cited by 173
Self-citationLung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options
Yousefi, M., Bahrami, T., Salmaninejad, A., Nosrati, R., Ghaffari, P., & Ghaffari, S. H. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0345-5 · Cited by 179
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
“Moreover, studies in lung cancer have shown that MET gene amplification is responsible for acquired resistance to EGFRtyrosine kinase inhibitors (Engelman et al, 2007).”
BackgroundResultSelf-citationHata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178
A genetic basis for the variation in the vulnerability of cancer to DNA damage
Yard, B. D., Adams, D. J., Chie, E. K., Tamayo, P., Battaglia, J. S., Gopal, P., Rogacki, K., Pearson, B. E., Phillips, J., Raymond, D. P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11428 · Cited by 175
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176
“Resistance there was mediated by MET-ErbB3 transactivation, leading to restored signaling via the PI3K/AKT pathway (27).”
InfluentialSelf-citationTsai, C.-F., Wang, Y.-T., Yen, H.-Y., Tsou, C.-C., Ku, W.-C., Lin, P.-Y., Chen, H.-Y., Nesvizhskii, A. I., Ishihama, Y., & Chen, Y.-J. (2015) · Nature Communications · doi:10.1038/ncomms7622 · Cited by 176
Nukaga, S., Yasuda, H., Tsuchihara, K., Hamamoto, J., Masuzawa, K., Kawada, I., Naoki, K., Matsumoto, S., Mimaki, S., Ikemura, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2359 · Cited by 175
Shah, R., & Lester, J. F. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 174
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
Liu, X., Newton, R. C., & Scherle, P. A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.11.005 · Cited by 175
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Choueiri, T. K., Plimack, E., Arkenau, H.-T., Jonasch, E., Heng, D. Y. C., Powles, T., Frigault, M. M., Clark, E. A., Handzel, A. A., Gardner, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2967 · Cited by 177
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00204 · Cited by 175
Immunotherapies: Exploiting the Immune System for Cancer Treatment
Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., Hernandez, J., Hung, F., Kaur, P., Teskey, G., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/9585614 · Cited by 175
Yan, S. B., Peek, V. L., Ajamie, R., Buchanan, S. G., Graff, J. R., Heidler, S. A., Hui, Y.-H., Huss, K. L., Konicek, B. W., Manro, J. R., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9912-9 · Cited by 167
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 174
Hartmaier, R. J., Markovets, A. A., Ahn, M. J., Sequist, L. V., Han, J.-Y., Cho, B. C., Yu, H. A., Kim, S.-W., Yang, J. C.-H., Lee, J.-S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0586 · Cited by 172
Self-citationLu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173
McCubrey, J. A., Steelman, L. S., Kempf, C. R., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 171
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Van Allen, E. M., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.005 · Cited by 172
Self-citationNew Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 172
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171
Self-citationMechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171
Function, regulation and pathological roles of the Gab/DOS docking proteins
Wöhrle, F. U., Daly, R. J., & Brummer, T. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-22 · Cited by 171
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
Malapelle, U., Sirera, R., Jantus-Lewintre, E., Reclusa, P., Calabuig-Fariñas, S., Blasco, A., Pisapia, P., Rolfo, C., & Camps, C. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1288568 · Cited by 171
Functional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170
“Comprehensive characterization of these aberrations is a necessary step in understanding disease etiology and advancing the development of targeted therapies [2,3,4,5,6,7].”
BackgroundThe paradoxical functions of EGFR during breast cancer progression
Ali, R., & Wendt, M. K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.42 · Cited by 167
Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.027 · Cited by 170
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
Neijssen, J., Cardoso, R. M. F., Chevalier, K. M., Wiegman, L., Valerius, T., Anderson, G. M., Moores, S. L., Schuurman, J., Parren, P. W. H. I., Strohl, W. R., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100641 · Cited by 167
CAO, M., SEIKE, M., SOENO, C., MIZUTANI, H., KITAMURA, K., MINEGISHI, Y., NORO, R., YOSHIMURA, A., CAI, L., & GEMMA, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1535 · Cited by 169
Activating MET kinase rearrangements in melanoma and Spitz tumours
Yeh, I., Botton, T., Talevich, E., Shain, A. H., Sparatta, A. J., de la Fouchardiere, A., Mully, T. W., North, J. P., Garrido, M. C., Gagnon, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8174 · Cited by 167
Crizotinib in Patients With MET-Amplified NSCLC
Camidge, D. R., Otterson, G. A., Clark, J. W., Ignatius Ou, S.-H., Weiss, J., Ades, S., Shapiro, G. I., Socinski, M. A., Murphy, D. A., Conte, U., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.010 · Cited by 166
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.